Software Acquisition Group Inc. II (SAII)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Software Acquisition Group Inc. II (SAII) trades at $8.98 with AI Score 44/100 (Grade C). Salarius Pharmaceuticals, Inc. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for SAII: SAII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SAII against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SAII: the 1 perspectives are evenly split.
How is this calculated? →Software Acquisition Group Inc. II (SAII) Healthcare & Pipeline Overview
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to creating innovative cancer treatments for pediatric, adolescent, and young adult patients, focusing on epigenetic-based therapies to address unmet needs in rare and aggressive cancers with limited treatment options.
What Is the Investment Thesis for SAII?
Salarius Pharmaceuticals presents a focused investment opportunity within the biopharmaceutical sector, specifically targeting rare cancers with epigenetic therapies. The company's lead candidate, Seclidemstat, is undergoing clinical trials, representing a potential value driver if successful. Key considerations include clinical trial outcomes, partnership opportunities, and the ability to secure funding for ongoing research and development. The company's focus on underserved patient populations and innovative therapeutic approaches could lead to significant growth if clinical milestones are achieved. However, the inherent risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles and competition, should be carefully evaluated.
Based on FMP financials and quantitative analysis
SAII Key Highlights
- Focus on developing therapies for cancers that disproportionately affect children, teens, and young adults.
- Lead program, Seclidemstat, targeting LSD1, an epigenetic enzyme, to treat sarcomas and other cancers.
- Seclidemstat is currently being evaluated in clinical trials for Ewing sarcoma and other advanced solid tumors.
- Commitment extends to rare cancers, where treatment options are often limited.
- Actively seeks collaborations and partnerships to expand its research and development efforts.
Who Are SAII's Competitors?
SAII is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| ARRY Array Technologies, Inc. | $6.94 | -0.37% | $1.07B | — |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| DMTX Dimension Therapeutics, Inc. | $5.95 | -0.42% | 60 | |
| ARIA ARIAD Pharmaceuticals, Inc. | $23.99 | +0.17% | 57 | |
| THPTF Techpoint, Inc. | $19.75 | +0.00% | $363.32M | 50 |
| ASRPF Asarina Pharma AB (publ) | $2.45 | +0.00% | $41.83M | 43 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SAII's Key Strengths?
- Focus on underserved patient populations with high unmet needs.
- Proprietary epigenetic drug discovery platform.
- Lead drug candidate, Seclidemstat, in clinical development.
- Experienced management team with expertise in drug development.
What Are SAII's Weaknesses?
- Clinical-stage company with no currently marketed products.
- Reliance on the success of Seclidemstat.
- Limited financial resources.
- High risk of clinical trial failure.
What Could Drive SAII Stock Higher?
- Data readouts from ongoing clinical trials of Seclidemstat in Ewing sarcoma and other advanced solid tumors.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Continued advancement of Seclidemstat through clinical development.
- Expansion of the company's epigenetic drug discovery platform.
What Are the Key Risks for SAII?
- Negative return on equity (-0.2%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures or delays.
- Regulatory hurdles and delays.
- Competition from other pharmaceutical companies.
- Dependence on the success of Seclidemstat.
- Limited financial resources.
What Are the Growth Opportunities for SAII?
- Seclidemstat Expansion: Salarius has the opportunity to expand the clinical development of Seclidemstat into additional cancer types beyond Ewing sarcoma and advanced solid tumors. This could involve initiating new clinical trials targeting other sarcomas or exploring its potential in hematological malignancies. The market for new cancer therapies is substantial, with a global oncology market projected to reach $286 billion by 2028, offering significant revenue potential if Seclidemstat proves effective in multiple indications.
- Partnerships and Collaborations: Strategic partnerships with larger pharmaceutical companies or research institutions could provide Salarius with access to additional funding, expertise, and resources to accelerate the development and commercialization of its pipeline. Collaborations could also facilitate the expansion of its research efforts into new areas of epigenetic drug discovery. The biopharmaceutical industry is characterized by frequent collaborations, with deal values often reaching hundreds of millions or even billions of dollars.
- Epigenetic Platform Expansion: Salarius could leverage its expertise in epigenetic drug discovery to develop additional therapeutic candidates targeting other epigenetic enzymes or pathways. This could involve expanding its research capabilities or acquiring new technologies to broaden its pipeline. The market for epigenetic therapies is growing, driven by increasing understanding of the role of epigenetics in cancer and other diseases.
- Orphan Drug Designation: Pursuing orphan drug designation for Seclidemstat in specific rare cancer indications could provide Salarius with several benefits, including market exclusivity, tax credits, and waived regulatory fees. Orphan drug designation is granted to therapies targeting rare diseases affecting fewer than 200,000 people in the United States, and it can significantly enhance the commercial attractiveness of a drug.
- Geographic Expansion: As Salarius's clinical programs advance, the company could explore opportunities to expand its geographic reach beyond North America. This could involve initiating clinical trials in Europe or Asia, or partnering with companies in those regions to commercialize its products. The global market for cancer therapies is substantial, with significant growth potential in emerging markets.
What Opportunities Does SAII Have?
- Expansion of Seclidemstat into additional cancer types.
- Strategic partnerships with larger pharmaceutical companies.
- Orphan drug designation for Seclidemstat.
- Advancements in epigenetic drug discovery.
What Threats Does SAII Face?
- Competition from other pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Difficulty securing funding.
What Are SAII's Competitive Advantages?
- Proprietary epigenetic drug discovery platform.
- Focus on rare cancers with limited treatment options.
- Patent protection for its lead drug candidate, Seclidemstat.
- Clinical data supporting the efficacy and safety of its therapies.
What Does SAII Do?
Salarius Pharmaceuticals, Inc., founded with a mission to combat cancers with high unmet needs, focuses on developing innovative therapies for pediatric, adolescent, and young adult (AYA) cancer patients. The company's core strategy revolves around epigenetic modifications, altering gene expression without changing the DNA sequence, to disrupt cancer cell growth and survival. Their lead programs, including Seclidemstat, target LSD1, an epigenetic enzyme, to treat sarcomas and other cancers. Seclidemstat is currently being evaluated in clinical trials for Ewing sarcoma and other advanced solid tumors. Salarius's commitment extends to rare cancers, where treatment options are often limited, and the company actively seeks collaborations and partnerships to expand its research and development efforts. By concentrating on epigenetic targets and rare cancer indications, Salarius aims to deliver transformative therapies and improve outcomes for patients facing challenging diagnoses. The company's geographic reach is primarily focused on North America, with potential for future expansion as clinical programs advance and partnerships broaden.
What Products and Services Does SAII Offer?
- Develops therapies for cancers affecting children, teens, and young adults.
- Focuses on epigenetic modifications to alter cancer cell behavior.
- Lead program targets LSD1, an epigenetic enzyme.
- Conducts clinical trials for Ewing sarcoma and other solid tumors.
- Seeks to address unmet needs in rare and aggressive cancers.
- Actively pursues collaborations and partnerships.
- Aims to deliver transformative therapies and improve patient outcomes.
How Does SAII Make Money?
- Develops and patents novel epigenetic therapies.
- Conducts preclinical and clinical research to evaluate drug candidates.
- Seeks regulatory approval for its therapies.
- May commercialize its products directly or through partnerships.
What Industry Does SAII Operate In?
The biopharmaceutical industry is characterized by intense research and development, high regulatory scrutiny, and significant investment in innovation. Salarius Pharmaceuticals operates within this landscape, focusing on epigenetic therapies for rare cancers. The market for cancer treatments is substantial and growing, driven by an aging population and advancements in diagnostics. Competition is fierce, with both large pharmaceutical companies and smaller biotechs vying for market share. Salarius differentiates itself through its focus on underserved patient populations and its epigenetic-based therapeutic approach.
Who Are SAII's Key Customers?
- Pediatric, adolescent, and young adult cancer patients.
- Oncologists and other healthcare professionals.
- Hospitals and cancer centers.
- Potential pharmaceutical partners.
How Software Acquisition Group Inc. II Is Valued
Relative to its peer group, SAII's quantitative score of 44/100 is below the peer average of 66/100.
ROE -0%Key Financial Metrics
Return on equity for Software Acquisition Group Inc. II stands at -0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. A current ratio of 5.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.
SAII Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting that leadership believes in significant growth ahead.
- Community sentiment has turned increasingly positive, with discussions highlighting innovative approaches and potential market impact.
- The company's focus on strategic acquisitions aligns well with current market trends, positioning it favorably against competitors.
- Analysts are noting an uptick in interest from institutional investors, which often signals a shift toward bullish sentiment in the stock.
Bear Case
- Despite positive sentiment, there are concerns about the overall market volatility which could affect investor confidence in tech acquisitions.
- Some community members express skepticism regarding the company's ability to integrate new acquisitions effectively, raising doubts about operational efficiency.
- Recent discussions have highlighted potential regulatory challenges that could impact future growth and profitability, making investors cautious.
- The lack of substantial revenue growth reported in recent quarters has led to bearish sentiments among certain investor segments, questioning the long-term viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
SAII Latest News
No recent news available for SAII.
SAII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SAII.
Price Targets
Wall Street price target analysis for SAII.
SAII MoonshotScore
What does this score mean?
The MoonshotScore rates SAII's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
SAII Healthcare Stock FAQ
What does SAII do?
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments for pediatric, adolescent, and young adult patients. Their primary focus is on epigenetic-based therapies, which modify gene expression without altering the DNA sequence, to disrupt cancer cell growth and survival. Their lead candidate, Seclidemstat, targets LSD1, an epigenetic enzyme, and is currently being evaluated in clinical trials for Ewing sarcoma and other advanced solid tumors. The company aims to address unmet needs in rare and aggressive cancers with limited treatment options.
What do analysts say about SAII stock?
Analyst coverage of Salarius Pharmaceuticals is limited, reflecting its status as a clinical-stage biopharmaceutical company. Key valuation metrics include the potential market size for Seclidemstat and the probability of success in clinical trials. Growth considerations center on the company's ability to advance its pipeline, secure partnerships, and obtain regulatory approvals. Investors should carefully evaluate the risks and uncertainties associated with clinical-stage drug development.
What are the main risks for SAII?
The main risks for Salarius Pharmaceuticals include clinical trial failures, regulatory hurdles, competition from other pharmaceutical companies, and dependence on the success of Seclidemstat. As a clinical-stage company, Salarius faces the inherent risk that its drug candidates may not demonstrate sufficient efficacy or safety in clinical trials. Regulatory delays or rejections could also significantly impact the company's timeline and financial prospects. Competition from larger pharmaceutical companies with greater resources poses a further challenge. Additionally, the company's reliance on Seclidemstat makes it vulnerable to setbacks if this drug candidate fails to achieve its clinical or commercial goals.
What are the key factors to evaluate for SAII?
Software Acquisition Group Inc. II (SAII) holds an AI score of 44/100 (low). Not financial advice.
How frequently does SAII data refresh on this page?
SAII prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SAII's recent stock price performance?
Software Acquisition Group Inc. II (SAII) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on underserved patient populations with high unmet needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SAII overvalued or undervalued right now?
Valuing Software Acquisition Group Inc. II (SAII) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SAII?
Before investing in Software Acquisition Group Inc. II (SAII), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide further insights.
- Limited analyst coverage may impact the accuracy of consensus estimates.